Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00541359 · ClinicalTrials.gov registry record · Phase 1
Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors
A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 2
- Study locations
NCT00541359: Completed Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, sponsored by City of Hope Medical Center.
NCT00541359 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by City of Hope Medical Center. The registered enrollment target is 54 participants, below the 500-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00541359, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 2
- Study locations
Study Summary
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with topotecan hydrochloride may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of topotecan hydrochloride when given together with bortezomib in treating patients with advanced solid tumors.
Conditions Studied
Interventions
- OTHER immunohistochemistry staining method
- OTHER pharmacological study
- DRUG bortezomib
- DRUG topotecan hydrochloride
Study Locations (2)
California
- City of Hope Medical Center - Duarte
- City of Hope Medical Group Inc - Pasadena
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2004-01 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
What the finished NCT00541359 record still lists
NCT00541359 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 500-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 4 interventions - of which immunohistochemistry staining method is the first listed.
NCT00541359 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00541359 about?
NCT00541359 is a clinical study titled "Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors". RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells ...
What is the current status of trial NCT00541359?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2004-01. Estimated completion is 2011-06.
What conditions does trial NCT00541359 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT00541359?
The interventions under investigation include: immunohistochemistry staining method (OTHER), pharmacological study (OTHER), bortezomib (DRUG), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00541359?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00541359 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00541359's enrollment target sits among peer trials
54 28th of 83 higher than 55 of 83 other Unspecified Adult Solid Tumor, Protocol Specific trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Unspecified Adult Solid Tumor, Protocol Specific trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
ACTIVE NOT RECRUITING · Phase 1
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
COMPLETED · Phase 1
-
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
BMS-599626 in Treating Patients With Metastatic Solid Tumors
COMPLETED · Phase 1
-
Indole-3-Carbinol in Preventing Cancer in Healthy Participants
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia